During baseline testing of 111 subjects for a one-year, randomized, placebo-controlled, double-blind study, researchers confirmed that although the level of macular pigment, comprised of lutein and zeaxanthin from the diet, varied widely among subjects, it had a significant impact on glare disability, photostress recovery time, and contrast enhancement.
During baseline testing of 111 subjects for a one-year, randomized, placebo-controlled, double-blind study, researchers confirmed that although the level of macular pigment, comprised of lutein and zeaxanthin from the diet, varied widely among subjects, it had a significant impact on glare disability, photostress recovery time, and contrast enhancement.
The baseline testing was done for a trial, now in progress, to determine whether supplementing with Kemin LC’s and DSM’s FloraGLO lutein (10 mg/day) and DSM’s OptiSharp zeaxanthin (2 mg/day) leads to improved visual performance by increasing the level of macular pigment. The test tablets feature DSM’s Actilease technology to maximise the absorption of lutein and zeaxanthin.
The baseline testing results were presented in May at the Association for Research in Vision and Ophthalmology meeting in Fort Lauderdale, FL.
Arla Foods to acquired whey nutrition business from Volac International
April 22nd 2024Arla Foods Ingredients has reached an agreement to acquire Volac’s Whey Nutrition business through a purchase of shares in Volac Whey Nutrition Holdings Limited and its subsidiary, Volac Whey Nutrition Limited and Volac Renewable Energy Limited.
The Nutritional Outlook Podcast Episode 29: 2024 Ingredients to Watch
January 31st 2024Nutritional Outlook interviews Scott Dicker, market insights director from market researcher SPINS, about ingredients and product categories nutraceutical and nutrition product manufacturers should watch in 2024.